Picard Medical, INC S-1 registration statements

Picard Medical, Inc. has filed a registration statement for the resale of up to 16,211,479 shares of its Common Stock by selling stockholders.

Picard Medical, Inc. is offering up to 21.1 million shares of common stock and associated warrants to raise approximately $9.1 million, facing significant net losses and a going concern doubt.

Picard Medical, Inc. has filed an S-1 registration statement detailing an offering of common stock, pre-funded warrants, and common warrants.

Picard Medical, Inc. filed an S-1/A registration statement for the resale of up to 17,000,000 shares of common stock by selling stockholders, including shares from senior secured notes and warrants, with no direct proceeds to the company from these sales.

Picard Medical, Inc. filed an S-1 registration statement for the resale of up to 17 million shares of common stock by selling stockholders, stemming from a recent $15 million senior secured notes and warrants private placement.

Picard Medical, Inc. is pursuing an initial public offering of 4.25 million shares at $3.50-$4.50 per share to fund operations and product development, despite a history of significant net losses and substantial doubt about its ability to continue as a going concern.

Picard Medical, a medical technology company specializing in the SynCardia Total Artificial Heart, is pursuing an initial public offering to raise $17 million, despite a history of substantial operating losses and a 'going concern' warning from its auditors.

Picard Medical, Inc., developer of the FDA-approved SynCardia Total Artificial Heart, is seeking to raise $17 million in its initial public offering to fund operations and product development, despite a history of substantial operating losses and auditor-raised going concern doubts.

Picard Medical, Inc., developer of the only FDA-approved total artificial heart, is seeking to raise $15.4 million in its initial public offering on the NYSE American, despite a history of substantial net losses and an auditor's warning about its ability to continue as a going concern.

Picard Medical, Inc., a medical technology company specializing in total artificial hearts, has filed an amended S-1 registration statement for its initial public offering, revealing continued significant operating losses, a substantial working capital deficit, and an auditor's going concern warning, despite ongoing product development and international expansion efforts.

Picard Medical, a medical technology company focused on artificial hearts, has filed an amendment to its Form S-1 registration statement, signaling progress towards its initial public offering and potential listing on the NYSE American.

Picard Medical, a medical technology company focused on artificial hearts, has filed an amendment to its S-1 registration statement, signaling progress towards its initial public offering and outlining plans for market expansion and product innovation.

Picard Medical, a company focused on artificial heart technology, has filed an S-1 registration statement for an initial public offering.